1. A fatal invasive Scedosporium apiospermum pulmonary infection in an adult patient with malignant lung adenocarcinoma
- Author
-
Zehra Bestepe Dursun, Hafize Sav, and Rabiye Altinbas
- Subjects
medicine.medical_specialty ,Posaconazole ,QH301-705.5 ,Pleural effusion ,Case Report ,Microbiology ,Gastroenterology ,chemistry.chemical_compound ,İnvasive fungal disease ,Internal medicine ,Amphotericin B ,medicine ,Biology (General) ,Voriconazole ,Lung ,scedosporium apiospermum ,business.industry ,Scedosporium apiospermum ,medicine.disease ,RC31-1245 ,invasive fungal disease ,febrile neutropenia ,Infectious Diseases ,medicine.anatomical_structure ,chemistry ,Caspofungin ,business ,Febrile neutropenia ,medicine.drug - Abstract
Background and Purpose: Scedosporium apiospermum complex as a ubiquitous environmental mold is increasingly reported to cause an invasive fungal infection in immunosuppressive hosts. Herein, we present the case of an immunosuppressive 54-year-old man who developed S. apiospermum complex lung infection and pulmonary adenocarcinoma. Case report: The patient had some complaints of dyspnea and cough during a neutropenic episode. The computed tomography (CT) scan of the patient revealed pleural effusion. After culturing the pleural fluid sample, the fungus was identified by microscopic examination and ITS sequencing. In addition, antifungal susceptibility testing was performed using the M38-A2 microdilution method. The minimum inhibitory concentrations of amphotericin B, voriconazole, posaconazole, and caspofungin were obtained as > 64, 0.06, 0.06, and 0.03 μg/mL, respectively. Voriconazole (administered in two doses of 6 mg/kg and a maximum of 250 mg) was preferred for treatment. The patient received antifungal treatment for 2 months; however, he was lost to follow-up. Conclusion: Scedosporium apiospermum complex should be considered a cause of systemic fungal infections in neutropenic patients. Furthermore, the determination of the in vitro antifungal susceptibilities of clinical strains may contribute to the development of therapeutic approaches.
- Published
- 2020
- Full Text
- View/download PDF